Delving into the Latest Updates on Norfloxacin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, NFLX

+ [28]

Target

Bacterial DNA gyrase

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases+ [2]

Active Indication

Dysentery, BacillaryGastrointestinal infectionTurista+ [12]

Inactive Indication

Cystitis

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

KYORIN Pharmaceutical Co., Ltd.Central Pharmaceutical JSC No. 3

Nichi-Iko Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

Merck Research Laboratories Massachusetts LLC

Eurofarma Laboratórios SA

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (15 Feb 1984),

Infectious Diseases

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC16H18FN3O3

InChIKeyOGJPXUAPXNRGGI-UHFFFAOYSA-N

CAS Registry70458-96-7

按有关生物等效性试验的规定，选择杏林制药株式会社为持证商的诺氟沙星片（商品名：バクシダール®，规格：100mg）为参比制剂，对云鹏医药集团有限公司生产并提供的受试制剂诺氟沙星胶囊（规格：0.1g）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹给药条件下的生物等效性。同时观察健康受试者口服受试制剂和参比制剂后的安全性。

[Translation]

According to the relevant provisions of bioequivalence test, the norfloxacin tablets (trade name: Bakushidal®, specification: 100mg) of Kyorin Pharmaceutical Co., Ltd. were selected as the reference preparation, and the test preparation norfloxacin capsules (specification: 0.1g) produced and provided by Yunpeng Pharmaceutical Group Co., Ltd. were subjected to fasting human bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. At the same time, the safety of the test preparation and the reference preparation after oral administration was observed in healthy subjects.

Start Date22 Dec 2024

Sponsor / Collaborator

Yunpeng Pharmaceutical Group Co Ltd.

CTR20240227

/ CompletedNot Applicable

诺氟沙星片在中国健康受试者空腹状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉的人体生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, two-period, two-sequence, single-dose, double-crossover bioequivalence study of norfloxacin tablets in Chinese healthy subjects under fasting condition

主要目的：以诺氟沙星片的体内药代动力学参数为生物等效性的评价指标，在中国健康受试者空腹状态下评估受试制剂（规格：0.1g；生产厂家：万邦德制药集团有限公司）和参比制剂（英文名：Norfloxacin Tablets；英文商品名：BACCIDAL；规格：0.1g；持证商：KYORIN Pharmaceutical Co.,Ltd.（日本杏林制药株式会社））的生物等效性。次要目的：观察空腹口服受试制剂和参比制剂的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the test preparation (specification: 0.1 g; manufacturer: Wanbangde Pharmaceutical Group Co., Ltd.) and the reference preparation (English name: Norfloxacin Tablets; English trade name: BACCIDAL; specification: 0.1 g; licensee: KYORIN Pharmaceutical Co., Ltd.) in Chinese healthy subjects under fasting state, using the in vivo pharmacokinetic parameters of norfloxacin tablets as the evaluation index of bioequivalence. Secondary objective: To observe the safety of the test preparation and the reference preparation when taken orally on an empty stomach.

Start Date16 Jun 2024

Sponsor / Collaborator

Wepon Pharmaceuticals Group Co. Ltd.

100 Clinical Results associated with Norfloxacin

Login to view more data

100 Translational Medicine associated with Norfloxacin

Login to view more data

100 Patents (Medical) associated with Norfloxacin

Login to view more data

19,627

Literatures (Medical) associated with Norfloxacin

31 Dec 2025·Plant Signaling & Behavior

Exploring the efficacy of drought tolerant, IAA-producing plant growth-promoting rhizobacteria for sustainable agriculture

Article

Author: Uzma, Malika ; Nisar, Atif ; Iqbal, Atia ; Gull, Tehseen ; Hasnain, Shahida ; Castro-Muñoz, Roberto ; Rahim, Muhammad Abdul ; Mahmoud, Mohamed H. ; Zongo, Eliasse

The growing human population and abiotic stresses pose significant threats to food security, with PGPR favorable as biofertilizers for plant growth and stress relief. In one study, soil samples from both cultivated and uncultivated plants in various cities were used to isolate rhizobacterial populations. Using 50 soil samples from both cultivated and uncultivated plants, isolated rhizobacterial populations were screened for various biochemical changes, PGP activities and morphological characteristics. A total of 199 rhizobacteria were isolated and screened for IAA production. The strain M28 produced maximum IAA 378.44 ± 2.5 µg ml^-1, M9 formed only 34.72 ± 0.15 µg ml^-1. About 19% of IAA producers were isolated from Multan, 18% Lahore, 15% from soils of Faisalabad and Sheikhupura, while 7% from Gujrat. The 21 isolates were drought tolerant to -0.14Mpa, 14 of those were PSB and 15 were N fixers. In PGP traits, maximum zinc solubility was expressed by M4 as 2 ± 0.5 cm of zone. The strain M22 produced amount of HCN, 40.12 ± 0.052 ppm. All isolates showed diverse behavior in biocompatibility, motility patterns and hydrophobicity. Selected drought tolerant strains were genetically identified by ribotyping. Multitrait PGPR could be effective biofertilizers rather than with single trait. The strain M28 having highest production of IAA, was gelatinase, methyl red positive and was also capable of nitrogen fixation. Moreover, it had maximum swimming (8.9 mm) and swarming (8.7 mm) activities after 24 h, indicating its best PGP traits for future use.

31 Dec 2025·Environmental Pollutants and Bioavailability

MnO₂-doped Hydrochar composite for peroxymonosulfate activation for norfloxacin degradation: mechanism and toxicity

Author: Pulimi, Mrudula ; Kumari, Madhu

In this study, peanut shell-derived Hydrochar was synthesized via hydrothermal carbonization and doped with MnO₂ nanorods, which served as a peroxymonosulfate activator for the degradation of norfloxacin.The primary aim was to valorize the natural waste by enhancing its properties for effective PMS activation.The composite was characterized by FTIR, FESEMEDX, XRD, BET and TGA. The catalytic performance of the MnO₂@HC composite showed an impressive 98.59% degradation of NOR.Optimum batch study conditions were established at pH 3, an MnO₂@HC dosage of 0.07 g L^-1, PMS concentration of 2 mm and a temperature of 50°C.The composite demonstrated strong reusability, with 75% NOR degradation maintained through five cycles.Radical scavenger tests confirmed that SO₄^.- and ^.OH radicals were the primary reactive species involved, while O₂^.- played a minor role in NOR degradationA degradation pathway was proposed based on High Resolution-Mass Spectrometer (HR-MS) anal., which identified intermediate products that exhibited reduced toxicity towards aquatic organisms.The mechanism involved cleavage of the quinolone and piperazinyl rings.These results highlight the practical applicability of the MnO₂@HC catalyst in aqueous environments.

01 Sep 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Engineering Z-scheme heterojunction via CuFe2O4-activated decahedral BiVO4 for tuned radical generation pathways in peroxymonosulfate activation for norfloxacin degradation

Article

Author: Zhang, Xian ; Wu, Xuran ; Niu, Can ; Hu, Yawen ; Li, Linsen

Constructing heterojunctions to activate peroxymonosulfate (PMS) addresses the challenge of poor photogenerated charge separation in individual materials, yet the effect of band alignment on reactive oxygen species (ROS) generation in composites is often overlooked. In this study, a novel Z-scheme system is successfully developed for PMS activation by integrating copper ferrite (CuFe₂O₄) with bismuth vanadate (BiVO₄) through hydrothermal and calcination methods. Notably, the production of hydroxyl radicals (HO•) and superoxide radicals (O₂^-•) is significantly boosted by water oxidation via valence band holes of BiVO₄ and oxygen (O₂) reduction by conduction band electrons of CuFe₂O₄, respectively. Moreover, the non-radical pathways via PMS activation are enhanced by the additional active sites generated through bimetallic redox cycling of ≡Cu⁺/≡Cu²⁺ and ≡Fe²⁺/≡Fe³⁺, coupled with the formation of oxygen vacancies on the CFO/BVO surface. The CuFe₂O₄@BiVO₄/Vis/PMS system achieves 96.15 % norfloxacin (NOR) degradation efficiency within 30 min, significantly outperforming the individual CuFe₂O₄ and BiVO₄ catalysts by 6.39 and 1.38 times, respectively. In the CuFe₂O₄@BiVO₄/Vis/PMS system, the HO• content increases by 2.20 times, the O₂^-• level by 1.49 times, and singlet oxygen (¹O₂) production by at least 3.55 times compared to the BiVO₄/Vis/PMS system. This system demonstrates excellent stability, recyclability, and broad pollutant degradation capability, offering a novel strategy for PMS activation and targeted ROS generation while advancing the design of visible-light-driven reusable photocatalysts for wastewater treatment.

1

News (Medical) associated with Norfloxacin

09 Feb 2021

·www.globenewswire.com

Global Urinary Tract Infection Treatment Markets, 2020-2027 - Market for Penicillin and Combination Drugs Segment to Grow at Highest Rate

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering. Market for Penicillin and Combination Drugs Segment to Grow at Highest CAGR during 2020-2027. The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent. Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment. R& D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for generic Nitrofurantoin capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used to treat UTI caused by Staphylococcus aureus, enterococci, etc. Further, in February 2020, a France-based pharmaceutical company announced Exblifep, a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime. i.e., the fourth-generation cephalosporin, which achieved primary endpoints in a clinical trial for complicated UTIs. Moreover, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in boots pharmacies throughout the UK. Additionally, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr to treat complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In July 2019, the US FDA approved Recarbrio drug to treat cUTI and complicated intra-abdominal infection in adults. In June 2018, Achaogen, Inc. received the US FDA approval for ZEMDRI to treat cUTIs in adults. In November 2018, Allergan, announced the launch of the FDA accepted supplemental drug AVYCAZ to treat cUTIs and complicated intra-abdominal infections patients between the age group of 3 months to 18 years. Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period. Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market. Key Topics Covered: 1. Introduction 2. Urinary Tract Infection Treatment Market - Key Takeaways 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Urinary Tract Infection Treatment Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.3 Expert Opinion 5. Urinary Tract Infection Treatment Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Growing Urinary Tract Infections 5.1.2 Aging Population 5.1.3 Emerging Computing Technologies for Urine Diagnostics 5.2 Market Restraints 5.2.1 Associated Effects of Medication 5.3 Market Opportunities 5.3.1 R&D in UTI Treatment 5.4 Future Trends 5.4.1 Nutritional Supplement in UTI 6. Urinary Tract Infection Treatment Market - Global Analysis 6.1 Global Urinary Tract Infection Treatment Market Revenue Forecast and Analysis 6.2 Global Urinary Tract Infection Treatment Market, By Geography - Forecast and Analysis 6.3 Market Positioning of Key Players 7. Urinary Tract Infection Treatment Market Analysis - By Drug Class 7.1 Overview 7.2 Urinary Tract Infection Treatment Market Revenue Share, by Drug Class (2019 and 2027) 7.3 Penicillin and Combinations 7.3.1 Overview 7.3.2 Penicillin and Combinations: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.3.3 Amoxicillin 7.3.4 Amoxicillin and Clavulanate Potassium 7.4 Quinolones 7.4.1 Overview 7.4.2 Quinolones: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.4.3 Ciprofloxaxin 7.4.4 Levofloxaxin 7.4.5 Nalidixic Acid 7.4.6 Norfloxacin 7.4.7 Others 7.5 Cephalosporin 7.6 Aminoglycoside Antibiotics 7.7 Sulphonamides 7.8 Nutritional Supplements 7.8.1 Overview 7.8.2 Nutritional Supplements: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.8.3 Cranberry Supplements 7.8.4 D-Mannose 7.8.5 Probiotics 7.8.6 Vitamin-C 8. Urinary Tract Infection Treatment Market Analysis - By Indication 8.1 Overview 8.2 Urinary Tract Infection Treatment Market Revenue Share, by Indication (2019 and 2027) 8.3 Complicated Urinary Tract Infections 8.4 Uncomplicated Urinary Tract Infections 9. Urinary Tract Infection Treatment Market Analysis - By Distribution Channel 9.1 Overview 9.2 Urinary Tract Infection Treatment Market Revenue Share, by Distribution Channel (2019 and 2027) 9.3 Hospital Pharmacies 9.4 Retail Pharmacies & Drug Stores 9.5 Gynaecology and Urology Clinics 9.6 Online Drug Stores 10. Urinary Tract Infection Treatment Market - Geographic Analysis 11. Impact of COVID-19 Pandemic on Global Urinary Tract Infection Treatment Market 12. Urinary Tract Infection Treatment Market-Industry Landscape Companies Mentioned Teva Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Ltd Mylan N.V. ALLERGAN Pfizer Inc. Cipla Ltd F. Hoffmann-La Roche Ltd Shionogi Inc. Amway DuPont Nutrition & Biosciences For more information about this report visit CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Collaborate

100 Deals associated with Norfloxacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00210	Norfloxacin	J01MA06 S01AE02	DB01059

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dysentery, Bacillary	Australia	Arrotex Pharmaceuticals Pty Ltd.	13 Nov 2001
Gastrointestinal infection	Australia	Arrotex Pharmaceuticals Pty Ltd.	13 Nov 2001
Turista	Australia	Arrotex Pharmaceuticals Pty Ltd.	13 Nov 2001
Corneal Ulcer	Japan	KYORIN Pharmaceutical Co., Ltd.	24 Nov 1992
Blepharitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Blepharitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Conjunctivitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Keratitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Gonorrhea	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Prostatitis	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Salmonella Infections	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Typhoid Fever	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Urinary Tract Infections	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Infectious Diseases	Japan	KYORIN Pharmaceutical Co., Ltd.	15 Feb 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystitis	Phase 3	-	Eurofarma Laboratórios SA	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03584724 (CTgov)	Early Phase 1	Uveitis	49	Norflo Oro (Norflo Oro)	ejhtpyjyyl(hplhnafngh) = rdiagiuukl gsyzmiimby (tpxltsddtd, 0.75) View more	-	28 Mar 2022
				Placebo for Norflo Oro (Placebo for Norflo Oro)	ejhtpyjyyl(hplhnafngh) = rkgbsduqpx gsyzmiimby (tpxltsddtd, 0.88) View more
EASL2020	Not Applicable	Spontaneous bacterial peritonitis	1,626	Norfloxacin	zmjamgowfu(wtfvxeaiuz) = epnxvpsmkr witrsqamtg (lgjsrjsgaw ) View more	Negative	27 Aug 2020
				Placebo	-
NCT01037959 (Pubmed \| Gastroenterology)	Phase 3	Fibrosis	291	Norfloxacin 400 mg	nhupolkmnr(dmeqrqngik) = zmcjbfdxkc vkppydtgsv (qylfatlhqi )	-	01 Dec 2018
				Placebo	nhupolkmnr(dmeqrqngik) = mjmdacrxxu vkppydtgsv (qylfatlhqi )
NCT00362752 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 2	Hepatopulmonary Syndrome	9	Placebo	uwgyzwnltm(ipmparouoc) = ukyzzsyaom pcedcxzcmv (erlwdnffek )	-	01 Dec 2010
AAAAI2010	Not Applicable	Hypersensitivity	-	Quinolones (Anaphylaxis patients)	xhlkvpfrjj(ykpdolnljn) = ebzuncaiba aeoymcdhum (spwhlnaqju )	Positive	01 Feb 2010
				Quinolones (Urticaria patients)	xhlkvpfrjj(ykpdolnljn) = ginlmvjlup aeoymcdhum (spwhlnaqju )
ARVO2002	Not Applicable	-	-	Levofloxacin 0.5%	unlqkyhnut(epybwuwrun) = uuxdkvfddw hyqfdffbcp (kxvfmuyazq, 3.53)	-	01 Dec 2002
				Norfloxacin 0.3%	unlqkyhnut(epybwuwrun) = pzmfiyuols hyqfdffbcp (kxvfmuyazq, 1.18)
NCT04159870 (Pubmed \| Gastroenterology)	Phase 3	Gastrointestinal Hemorrhage	119	Norfloxacin	tjqxfbdtcb(fvuzlbqpse) = sfbllxpntp aenypzrgck (mxnvnaekri ) View more	-	01 Oct 1992
				Norfloxacin (Control)	sxxwtiuued(tyvouiqdga) = zftmnpiqes qhnkkotdac (dmlwhjootm ) View more